Survodutide: Reference Overview and Reconstitution Notes

Survodutide is an investigational peptide (a small molecule made of amino acids, the same building blocks found in proteins) that is being studied for its effects on metabolism and weight regulation. It targets two cell receptors at once and is not FDA approved.

Survodutide

What it is

Survodutide, also known by its lab code BI 456906, is an investigational peptide. It is designed to activate two receptors at once: the glucagon receptor (GCGR) and the GLP-1 receptor. A receptor is like a lock on the surface of a cell. When the right molecule (the "key") fits into it, the cell gets a signal to do something. Survodutide acts as a key for both locks at the same time, which is why it is called a dual agonist.

Its structure is based on glucagon, a natural signaling molecule in the body, and a fatty chain has been attached to it. Think of that fatty chain like a slow-release anchor. It keeps the molecule active in the body longer, which is why research protocols often use a once-weekly schedule.

Key point: Survodutide is an investigational dual agonist that targets both the GLP-1 and glucagon receptors. It is being studied for effects on metabolism and liver health.

Research context and categorization

Survodutide belongs to a group of compounds studied for metabolism and weight regulation. It works on two receptor pathways at once and is being developed by Boehringer Ingelheim in collaboration with Zealand Pharma.

In lab research, survodutide is studied for its effects on body weight, blood sugar levels, and liver health. GLP-1 receptor activity is commonly linked to appetite and how the stomach processes food. Glucagon receptor activity is commonly linked to energy use and how the liver processes fat.

Much of the published research focuses on obesity, type 2 diabetes, and a liver condition called MASH (metabolic dysfunction-associated steatohepatitis, previously called NASH). MASH is a condition where too much fat builds up in the liver and causes damage over time, sometimes leading to scarring called fibrosis.

Because survodutide is not FDA approved, all of these uses are investigational. They are the subject of ongoing trials and are not confirmed or approved benefits. Descriptions of what it is studied for should not be read as proven outcomes.

Status

• Regulatory status: Research-only and investigational. Survodutide is not FDA approved for any use. It is in late-stage clinical development. The FDA has given it Breakthrough Therapy designation for non-cirrhotic MASH with fibrosis. This is a special development pathway that can help speed up the review process. It is not an approval.
• Sport status: Survodutide is not specifically named on the WADA Prohibited List. WADA (the World Anti-Doping Agency) sets the rules about substances in competitive sports. The broader class of GLP-1 receptor agonists is currently on WADA's Monitoring Program, which means it is being watched but is not yet prohibited. Monitoring status can change, so always check the current-year list before relying on this information.

Reconstitution notes (general)

Survodutide is usually supplied as a lyophilized (freeze-dried) powder. Think of it like instant coffee: the water has been removed so the powder stays stable during storage. Before lab use, it is mixed back with bacteriostatic water (sterile water with a small amount of preservative). This mixing process is called reconstitution.

The concentration of the finished solution comes from a simple calculation: divide the amount of peptide in milligrams by the amount of bacteriostatic water added in milliliters.

For example, a 5 mg vial mixed with 2 mL of bacteriostatic water gives 2.5 mg/mL. The same vial mixed with only 1 mL gives 5 mg/mL. A concentration calculator is available at peptide calculator.

Dilution and handling notes (compound-specific)

Survodutide comes as a freeze-dried powder and must be mixed before use. It does not arrive as a ready-to-use liquid. Research references commonly pair 5 mg and 10 mg vials with roughly 1 mL to 2 mL of bacteriostatic water. The amount of water to add is driven by the concentration a given protocol needs, not by how much water the powder can absorb.

Practical Handling Guidelines

• Let the sealed vial warm to room temperature before opening. This reduces condensation (unwanted water droplets) from forming inside.
• Add the water slowly down the inner glass wall of the vial rather than directly onto the powder. Then swirl or roll the vial gently. Do not shake it. Shaking can cause foaming, which puts stress on this type of peptide (one that carries an attached fatty chain).
• The powder generally dissolves quickly and clears within about 30 to 60 seconds. A properly reconstituted solution should be clear and colorless.
• Inspect the solution before lab use. Cloudiness, unusual color, visible particles, or floating bits are signs that the material should not be used.

Handling and storage

Store the reconstituted solution in a refrigerator at 2 to 8 C and keep it away from direct light. Wipe the rubber stopper with an alcohol swab before each withdrawal. Write the date it was mixed on the vial label.

A refrigerated working solution is commonly referenced as usable for about 4 weeks (roughly 28 days). Avoid freezing and thawing it more than once. Discard the solution if it becomes cloudy, changes color, or develops floating particles.

Related reading

• VK2735
• ACE-031
• Amycretin
• How Reconstitution Works
• How Long Does a Reconstituted Vial Last?

Tools and supplies

• peptide calculator
• Bacteriostatic Water 30 ml
• Gansulin Metal Reusable Pen
• 3 ml Glass Cartridges (10-pack)
• Complete Starter Kit

Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.

Frequently asked questions

What receptors does survodutide target?

Survodutide is a dual agonist designed to activate both the GLP-1 receptor and the glucagon receptor (GCGR) simultaneously. Its glucagon-based structure includes an attached fatty chain that extends its duration of activity.

What is the regulatory status of survodutide?

Survodutide is investigational and not FDA-approved for any use. It holds FDA Breakthrough Therapy designation for non-cirrhotic MASH with fibrosis, which can expedite review but is not itself an approval.

How is lyophilized survodutide reconstituted for laboratory research?

Lyophilized survodutide powder is reconstituted by slowly introducing bacteriostatic water into the vial, gently swirling until fully dissolved, then visually inspecting for clarity and particulates before lab use.

What the research community gets wrong about survodutide

• Treating it like a single GLP-1 agonist. Survodutide acts on two receptors at once (the glucagon receptor and the GLP-1 receptor). It is a different molecule from a GLP-1-only compound, so filing it next to those references, or copying their handling notes onto your vial labels, can lead to mistakes at the bench.
• Logging the code name and the drug name as two materials. Survodutide and BI 456906 are the same compound. Recording them as separate items splits your inventory counts and makes reconstitution records harder to reconcile.
• Calling it approved. Survodutide is investigational and not FDA approved. Breakthrough Therapy designation is a faster review pathway, not an approval, so any vial label or spreadsheet marked "approved" is inaccurate.
• Shaking the vial to speed things up. The attached fatty chain makes this peptide prone to foaming. Adding water down the glass wall and swirling gently protects the material better than shaking, which stresses it at the air and liquid boundary.
• Assuming the mixed solution keeps forever. The freeze-dried powder is stable in storage, but a reconstituted working solution is not. Assuming powder-like stability leads people to keep refrigerated solutions well past the window commonly referenced in handling notes.

From our bench: If you have reconstituted a survodutide vial, we want your real numbers. Time how many seconds the powder takes to fully clear after you add bacteriostatic water and swirl, and note whether any foam formed on the surface. Record the concentration you targeted (mg divided by mL) and how the solution looked at each check while refrigerated at 2 to 8 C. Send us your measured observations and we will add them here, with no invented figures.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. Survodutide, PubChem Compound CID 168429725 (molecular formula C192H289N47O61)
5. Sanyal AJ et al., A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis, N Engl J Med 2024 (PMID 38847460)
6. le Roux CW et al., Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a dose-finding phase 2 trial, Lancet Diabetes Endocrinol 2024 (PMID 38330987)